Literature DB >> 21296871

Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.

Anna Woloszynska-Read1, Wa Zhang, Jihnhee Yu, Petra A Link, Paulette Mhawech-Fauceglia, Golda Collamat, Stacey N Akers, Kelly R Ostler, Lucy A Godley, Kunle Odunsi, Adam R Karpf.   

Abstract

PURPOSE: Cancer germline (CG) antigens are frequently expressed and hypomethylated in epithelial ovarian cancer (EOC), but the relationship of this phenomenon to global DNA hypomethylation is unknown. In addition, the potential mechanisms leading to DNA hypomethylation, and its clinicopathologic significance in EOC, have not been determined. EXPERIMENTAL
DESIGN: We used quantitative mRNA expression and DNA methylation analyses to determine the relationship between expression and methylation of X-linked (MAGE-A1, NY-ESO-1, XAGE-1) and autosomal (BORIS, SOHLH2) CG genes, global DNA methylation (5mdC levels, LINE-1, Alu, and Sat-α methylation), and clinicopathology, using 75 EOC samples. In addition, we examined the association between these parameters and a number of mechanisms proposed to contribute to DNA hypomethylation in cancer.
RESULTS: CG genes were coordinately expressed in EOC and this was associated with promoter DNA hypomethylation. Hypomethylation of CG promoters was highly correlated and strongly associated with LINE-1 and Alu methylation, moderately with 5mdC levels, and rarely with Sat-α methylation. BORIS and LINE-1 hypomethylation, and BORIS expression, were associated with advanced stage. GADD45A expression, MTHFR genotype, DNMT3B isoform expression, and BORIS mRNA expression did not associate with methylation parameters. In contrast, the BORIS/CTCF expression ratio was associated with DNA hypomethylation, and furthermore correlated with advanced stage and decreased survival.
CONCLUSIONS: DNA hypomethylation coordinately affects CG antigen gene promoters and specific repetitive DNA elements in EOC, and correlates with advanced stage disease. The BORIS/CTCF mRNA expression ratio is closely associated with DNA hypomethylation and confers poor prognosis in EOC. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296871      PMCID: PMC3079045          DOI: 10.1158/1078-0432.CCR-10-2315

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.

Authors:  Anna Woloszynska-Read; Smitha R James; Chajoun Song; Boquan Jin; Kunle Odunsi; Adam R Karpf
Journal:  Cancer Immun       Date:  2010-07-23

Review 2.  DNA methylation and human disease.

Authors:  Keith D Robertson
Journal:  Nat Rev Genet       Date:  2005-08       Impact factor: 53.242

3.  Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells.

Authors:  Adam R Karpf; Sei-ichi Matsui
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

4.  Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.

Authors:  Julie A Hong; Yang Kang; Ziedulla Abdullaev; Patrick T Flanagan; Svetlana D Pack; Maria R Fischette; Mina T Adnani; Dmitri I Loukinov; Sergei Vatolin; John I Risinger; Mary Custer; G Aaron Chen; Ming Zhao; Dao M Nguyen; J Carl Barrett; Victor V Lobanenkov; David S Schrump
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 5.  Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.

Authors:  Stacey N Akers; Kunle Odunsi; Adam R Karpf
Journal:  Future Oncol       Date:  2010-05       Impact factor: 3.404

6.  Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells.

Authors:  Petra A Link; Omkaram Gangisetty; Smitha R James; Anna Woloszynska-Read; Makoto Tachibana; Yoichi Shinkai; Adam R Karpf
Journal:  Mol Cancer Res       Date:  2009-06-16       Impact factor: 5.852

7.  DNA hypomethylation and ovarian cancer biology.

Authors:  Martin Widschwendter; Guanchao Jiang; Christian Woods; Hannes M Müller; Heidi Fiegl; Georg Goebel; Christian Marth; Elisabeth Müller-Holzner; Alain G Zeimet; Peter W Laird; Melanie Ehrlich
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

8.  NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.

Authors:  Kunle Odunsi; Achim A Jungbluth; Elisabeth Stockert; Feng Qian; Sacha Gnjatic; Jonathan Tammela; Marilyn Intengan; Amy Beck; Bernadette Keitz; Darren Santiago; Barbara Williamson; Matthew J Scanlan; Gerd Ritter; Yao-Tseng Chen; Deborah Driscoll; Ashwani Sood; Shashikant Lele; Lloyd J Old
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

9.  Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.

Authors:  Ian M Smith; Chad A Glazer; Suhail K Mithani; Michael F Ochs; Wenyue Sun; Sheetal Bhan; Alexander Vostrov; Ziedulla Abdullaev; Victor Lobanenkov; Andrew Gray; Chunyan Liu; Steven S Chang; Kimberly L Ostrow; William H Westra; Shahnaz Begum; Mousumi Dhara; Joseph Califano
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

10.  DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage.

Authors:  George S Watts; Bernard W Futscher; Nicholas Holtan; Koen Degeest; Frederick E Domann; Stephen L Rose
Journal:  BMC Med Genomics       Date:  2008-09-30       Impact factor: 3.063

View more
  45 in total

1.  BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells.

Authors:  Sanne Marlijn Janssen; Roy Moscona; Mounib Elchebly; Andreas Ioannis Papadakis; Margaret Redpath; Hangjun Wang; Eitan Rubin; Léon Cornelis van Kempen; Alan Spatz
Journal:  Cell Death Discov       Date:  2020-01-02

2.  Epigenetic activation of POTE genes in ovarian cancer.

Authors:  Ashok Sharma; Mustafa Albahrani; Wa Zhang; Christina N Kufel; Smitha R James; Kunle Odunsi; David Klinkebiel; Adam R Karpf
Journal:  Epigenetics       Date:  2019-03-04       Impact factor: 4.528

3.  Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

Authors:  Pragya Srivastava; Benjamin E Paluch; Junko Matsuzaki; Smitha R James; Golda Collamat-Lai; Julia Karbach; Michael J Nemeth; Pietro Taverna; Adam R Karpf; Elizabeth A Griffiths
Journal:  Leuk Res       Date:  2014-09-10       Impact factor: 3.156

Review 4.  Combining Epigenetic and Immunotherapy to Combat Cancer.

Authors:  Katherine B Chiappinelli; Cynthia A Zahnow; Nita Ahuja; Stephen B Baylin
Journal:  Cancer Res       Date:  2016-03-17       Impact factor: 12.701

5.  The male germ cell gene regulator CTCFL is functionally different from CTCF and binds CTCF-like consensus sites in a nucleosome composition-dependent manner.

Authors:  Frank Sleutels; Widia Soochit; Marek Bartkuhn; Helen Heath; Sven Dienstbach; Philipp Bergmaier; Vedran Franke; Manuel Rosa-Garrido; Suzanne van de Nobelen; Lisa Caesar; Michael van der Reijden; Jan Christian Bryne; Wilfred van Ijcken; J Anton Grootegoed; M Dolores Delgado; Boris Lenhard; Rainer Renkawitz; Frank Grosveld; Niels Galjart
Journal:  Epigenetics Chromatin       Date:  2012-06-18       Impact factor: 4.954

6.  Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter.

Authors:  Natsuki Kosaka-Suzuki; Teruhiko Suzuki; Elena M Pugacheva; Alexander A Vostrov; Herbert C Morse; Dmitri Loukinov; Victor Lobanenkov
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

7.  DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11.

Authors:  Smitha R James; Carlos D Cedeno; Ashok Sharma; Wa Zhang; James L Mohler; Kunle Odunsi; Elizabeth M Wilson; Adam R Karpf
Journal:  Epigenetics       Date:  2013-07-09       Impact factor: 4.528

8.  BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma.

Authors:  Kefei Chen; Wenqing Huang; Bin Huang; YongGang Wei; Bo Li; Yan Ge; Yang Qin
Journal:  Genet Test Mol Biomarkers       Date:  2012-12-13

9.  Features of ovarian cancer in Lynch syndrome (Review).

Authors:  Kanako Nakamura; Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Hiroyuki Nomura; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-08-20

10.  BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.

Authors:  Petra A Link; Wa Zhang; Kunle Odunsi; Adam R Karpf
Journal:  Cancer Immun       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.